Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene profiling in carcinoma cell during EMT

ABSTRACT: Modulation of several waves of gene expression during FGF-1 induced Epithelial-mesenchymal transition of carcinoma cells . In vitro FGF-1 induced EMT study using NBTII rat bladder carcinoma cells Keywords: time course ; EMT ; cancer cell line ; FGF-1

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE5664 | GEO | 2008/02/20

SECONDARY ACCESSION(S): PRJNA96939

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of rat Fcarcinoma cells during FGF-1 induced Epithelial-mesenchymal transition

Project description:Modulation of several waves of gene expression during FGF-1 induced Epithelial-mesenchymal transition of carcinoma cells . In vitro FGF-1 induced EMT study using NBTII rat bladder carcinoma cells Experiment Overall Design: NBTII and NBTII-FGFR1 cells were induced by FGF-1. Total RNA were prepared from stimulated and control cells at time 0.5, 2, 6, 24 and 48 hours. Except for control and 0.5 hour stimulated cells, the experiment was done in duplicate for each cell line type

2008-04-07 | E-GEOD-5664 | biostudies-arrayexpress

RhoJ controls EMT associated resistance to chemotherapy

Project description:The resistance of cancer cells to therapy is responsible for the death of most cancer patients. Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to therapy in different cancer cells. However, the mechanisms by which EMT mediates resistance to therapy remain poorly understood. Here, using a mouse model of skin squamous cell carcinoma (SCC) undergoing spontaneous EMT during tumorigenesis, we found that EMT tumor cells were highly resistant to a wide range of anti-cancer therapy both in-vivo and in-vitro. Using gain and loss of function in vitro and in vivo, we uncovered that RhoJ, a small GTPase preferentially expressed in EMT cancer cells, controls resistance to therapy. Using genome-wide transcriptomic and proteomic profiling, we found that RhoJ regulates EMT associated resistance to chemotherapy by promoting DNA damage response and the formation of new replication forks allowing tumor cells to repair DNA lesions more rapidly and survive under the replicative stress induced by chemotherapy. Using affinity-purification followed by mass spectrometry, we found that RhoJ interacts with proteins regulating nuclear actin and the inhibition of actin polymerization sensitizes EMT tumor cells to chemotherapy induced cell death in a Rhoj dependent manner. Altogether, our study uncovers the role and the mechanisms by which RhoJ acts as a key regulator of EMT associated resistance to chemotherapy.

2023-01-13 | PXD038278 | Pride

RhoJ controls EMT associated resistance to chemotherapy

Project description:The resistance of cancer cell to therapy is responsible of the death of most cancer patients. Epithelial to mesenchymal transitions (EMT) has been associated with resistance to therapy in different cancer cells. However, the mechanisms by which EMT mediates resistance to therapy remain poorly understood. Here, using a mouse model of skin squamous cell carcinoma (SCC) undergoing spontaneous EMT during tumorigenesis, we identified EMT tumor subpopulations displaying different intrinsic resistance mechanisms to a wide range of anti-cancer therapy both in-vivo and in-vitro. We found that RhoJ, a small GTPase, preferentially expressed in EMT cancer cells controls resistance to therapy. Using genome-wide transcriptomic and proteomic profiling combined with functional assays following loss of RhoJ functions, we found that RhoJ regulated EMT associated resistance to chemotherapy by promoting DNA damage response and the formation of new replication forks allowing EMT tumor cells to repair DNA lesions more rapidly and survive under the replicative stress induced by chemotherapy. Altogether, our study uncovers RhoJ as a key regulator of EMT associated resistance to chemotherapy with important implications for the development of new strategies to overcome resistance to therapy in cancer.

2023-01-13 | PXD025737 | Pride

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

Project description:The progression of conventional urothelial carcinoma (UC) of the bladder to a tumor with a mesenchymal phenotype, referred to as sarcomatoid carcinoma (SARC), is signified by a high propensity for regional and distant metastasis resulting in shorter survival. We report a comprehensive retrospective analysis of 28 cases of SARCs and 84 cases of conventional UCs. A TCGA cohort of 408 muscle-invasive bladder cancers was used as a reference cohort. SARCs showed a distinct mutational landscape with enrichment of p53, PIK3CA, and RB1 mutations. They developed from basal precursor conventional UCs and could be divided into a basal subtype and the most aggressive mesenchymal subtype. Expression analysis showed that SARCs are driven by dysregulation of cell cycle and EMT regulatory networks and nearly half exhibited an immune infiltration phenotype with PDL1 upregulation. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer.

2019-05-07 | GSE128192 | GEO

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer [RT-PCR]

2019-03-14 | GSE128277 | GEO

The dynamics of chromatin accessibility during EMT

Project description:The power of our genome-wide survey lies in that we were able to query chromatin accessibility changes concurrently with those in DNA methylation. We identified both opening and closing events, predominantly independent of DNA methylation, in both systems. Our results have powerful implications for future basic and clinical research on this developmental process and its resurfacing during cancer cell metastasis. To address epigenetic changes that mediate EMT, we used two models in the human system: EMT induced by the transcriptional repressor Twist as well as EMT induced by TGF-beta. We performed AcceSssIble on these cells at several time points through the course of the transition and identified genes that need to be repressed to allow for the process.

2015-12-31 | E-GEOD-63366 | biostudies-arrayexpress

A systematic analysis of the time series gene expression in TGF-beta induced EMT by Next-generation sequencing

Project description:The goal of this study is to characterize time course gene expression profiles during TGF-beta induced EMT. In particular, we aim to identify and characterize master transcription factors regulate the transition into partial-EMT state. A time series mRNA profile in A549 cells is generated from TGF-beta induced EMT samples during 0h,6h,12h,24h,36h,48h,72h and 96h by deep sequencing, in duplicate, using Illumina HiSeq 2500

2016-03-02 | E-GEOD-69667 | biostudies-arrayexpress

A systematic analysis of the time series gene expression in TGF-beta induced EMT by Next-generation sequencing

2016-03-02 | GSE69667 | GEO

Expression data from rat orthotopic bladder cancer

Project description:In the development and progression of bladder cancer, there are many genetic changes. We established a SD rat orthotopic bladder cancer model through intravesical instillation of N-methyl-nitrosourea and pathologic diagnosis is bladder transtional cell carcinomal (BTCC). We used microarrays to analysis the gene expression changes among these rat bladder carcinoma, adjacent normal tissues and bladder tissues of normal rats.

2016-01-12 | GSE76702 | GEO

miR-1199-5p and Zeb1: a novel double-negative feedback coordinating EMT and tumour cell invasion (miRNA-seq)

Project description:We performed miRNA-sequencing in a detailed time course of a TGFbeta-induced EMT in normal mammary gland cells and discovered 32 strongly, differentially expressed miRNAs.

2017-11-09 | GSE86025 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data